Michael F. Huang - 21 Jan 2026 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Reporting relationship: Sr. VP of Clinical Development
Issuer ticker: SLNO
Reported as of: 21 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 18:02:38 UTC
Prior SEC filing: 17 Dec 2025
Next SEC filing: 31 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Anish Bhatnagar, Attorney-in-Fact

Key filing fact

Michael F. Huang filed Form 4 for SOLENO THERAPEUTICS INC (SLNO) on 23 Jan 2026.

Key facts

This page summarizes Michael F. Huang's Form 4 filing for SOLENO THERAPEUTICS INC (SLNO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jan 2026, 18:02.

Change

Previous filing in this sequence was filed on 17 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002019992 Primary reporting owner

Huang Michael F.

Relationship: Sr. VP of Clinical Development
Address: 100 MARINE PARKWAY, SUITE 400, REDWOOD CITY
Signature: /s/ Anish Bhatnagar, Attorney-in-Fact
Signature date: 23 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLNO transaction

Common Stock

Award

Transaction value: $0
Shares: +10,400
Change %: +29%
Price: $0.000000
Shares after: 46,405
Date: 21 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLNO transaction Derivative

Employee stock option (right to buy)

Award

Transaction value: $0
Shares: +11,900
Change %
Price: $0.000000
Shares after: 11,900
Date: 21 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,900
Exercise price: $43.65
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.

Footnote F2

Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Footnote F3

1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.